On Friday, May 17, 2019, the Centers for Medicare and Medicaid Services issued Medicaid Drug Rebate Program (MDRP) manufacturer release #110. The release includes information for manufacturers regarding treatment of rebates paid to Medicare Advantage Prescription Drug (MA-PD) plans for Part B drugs when calculating MDRP pricing metrics, such as Average Manufacturers Price (AMP) and Best Price, as well as Average Sales Price (ASP); further instructions for manufacturers that wish to terminate their National Drug Rebate Agreement (NDRA) to assure prompt receipt by CMS of the termination notice; and further information regarding new manufacturer requests for an NDRA with respect to optional and mandatory effective dates for state coverage of new covered outpatient drugs.
lunes, 20 de mayo de 2019
Suscribirse a:
Enviar comentarios (Atom)
No hay comentarios:
Publicar un comentario